AMLX earnings analysis
What we found in AMLX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Amylyx Pharmaceuticals achieved a Q1 2026 net loss of $41.3 million, reflecting a negative EPS of -$0.37, beating street expectations of -$0.34. Significant R&D expenditures were noted at $27.6 million, driven primarily by avexitide clinical trials, and the firm's cash reserves stand at $279.8 million, projected to sustain operations until 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Beat Expectations
- Reported EPS of -$0.37 beat estimates of -$0.34.
- Increased R&D Expenses
- R&D expenses rose to $27.6 million, up from $22.1 million YoY, primarily due to Phase 3 clinical trials.
- Cash Reserves Extended
- Cash and equivalents totaled $279.8 million, sufficient to fund operations through 2028.
- Operating Loss Declined
- Net loss of $41.3 million in Q1 2026, compared to $35.9 million in Q1 2025.
- Improved Cash Flow from Investing
- Net cash provided by investing activities was $36.3 million, a significant improvement from a $43.7 million outflow last year.
- Strong Interest Income
- Interest income for the quarter increased to $2.57 million from $2.23 million YoY.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent Net Loss
- Net loss increased to $41.3 million compared to a $35.9 million loss in the prior year.
- Clinical Trial Risks
- Increased reliance on avexitide development could jeopardize future financial performance.
- Cash Flow Constraints
- Continued negative operating cash flow of $36.88 million may limit operational flexibility.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.37
What they said about what is next.
Management anticipates cash runway sufficient through 2028 but deferred numeric guidance on future revenues.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 3, 2026
- Amylyx remains a clinical-stage biopharma focused on avexitide (GLP-1 receptor antagonist for PBH) and a neurodegeneration program (AMX0035, AMX0114). The company reports no meaningful product revenue (reported revenue…
- 10-Q · November 6, 2025
- Amylyx reported Q3 2025 product revenue of $0 and GAAP net loss per share of $(0.37), an improvement vs. Q3 2024. Operating loss narrowed to $(36,027) (in thousands) driven by lower operating expenses and a $256.7…
- 10-Q · August 7, 2025
- Amylyx reported Q2 2025 GAAP net loss of $41,443 (per the condensed statements) with GAAP diluted EPS of $(0.46). Product revenue remained nil (Product revenue, net $—) while operating expenses declined to $42,857 from…
- 10-Q · May 8, 2025
- Amylyx reported Q1 2025 GAAP net loss of $35,907,000 (EPS -$0.42), a sizable improvement versus Q1 2024 net loss of $118,793,000 (EPS -$1.75). Product revenue fell to $0 in the quarter (Q1 2024: $88,643,000) as the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AMLX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever